# Blackrock Health Sciences Trust (BME) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Financial Services / Capital Markets. Price $46.69, market value $607 million.

## Valuation
- **P/E (trailing): 5.8×** (5-yr avg 16.8×, 3-yr avg 16.8×). Blackrock Health Sciences Trust trades at 5.8× trailing earnings, well below its own five-year average of 16.8×: cheap by its own standards. The Financial Services median in the September 2026 study was 13.1×.
- **Price / sales: 7.8×**. Each dollar of revenue is priced at 7.8×.
- **Price / book: 1.1×**. The shares trade at 1.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 9.0%** (5-yr avg 7.8%). Free cash flow equals 9.0% of the market value, in line with its five-year average of 7.8%. Above 5% is generally attractive.
- **Earnings yield: 17.3%**. The inverse of the P/E: 17.3% of the price is earned each year.

## Profitability
- **Net margin: 99.3%**. 99.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 13.5%**. 13.5% on shareholders' equity is solid.
- **Return on assets: 13.5%**. Each dollar of assets produces 13.5% of profit; low single digits are normal for banks and insurers.

## Growth
- **Revenue growth (1 yr): 222.1%**. Revenue grew 222.1% over the last year.
- **EPS growth (1 yr): 263.2%**. Earnings per share rose 263.2%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 6.74%** ($3.15 per share, trailing). Blackrock Health Sciences Trust yields 6.74%, high enough to check carefully: yields this high often precede a cut.
- **Payout ratio: 53%** (74% of free cash flow). 53% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 8**. 8 straight years of increases.
- **Dividend growth (5 yr): 5.5%/yr** (1-yr 20.7%). The dividend has grown 5.5% a year over five years.
- **Shareholder yield: 9.0%**. Dividends plus net buybacks return 9.0% of the market value a year.

## Price and momentum
- **Total return (1 yr): 29.8%** (YTD 19.5%, 3-mo 8.0%). The shares are up 29.8% over twelve months including dividends.
- **From 52-week high: -1.5%** (24.5% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 69**. An RSI of 69 is neutral.
- **Beta (1 yr): 0.33** (volatility 14%). Beta of 0.33 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BME · Page: https://foliofundamentals.com/stocks/bme

Not investment advice.